SCHEMBL2409358

SCHEMBL2409358

Cc1cccc(C(=O)NC(C)c2ccc(C(=O)NO)cc2)c1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 2/20 0.67
HDAC6 Q9UBN7 2/20 0.67
SMN1; SMN2 Q16637 3/20 0.57
ALDH1A1 P00352 2/20 0.57
GPR139 Q6DWJ6 1/20 0.56
LMNA P02545 1/20 0.54
ATM Q13315 1/20 0.53
TAS1R3 Q7RTX0 2/20 0.51
TAS1R1 Q7RTX1 2/20 0.51
NPC1 O15118 1/20 0.50
CYP1A2 P05177 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
HDAC1 Q13547 2/20 0.49
POLB P06746 1/20 0.49
MAPT P10636 1/20 0.49
CTDSP1 Q9GZU7 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12279819 0.86 ALDH1A1 (0.57) HDAC8HDAC6SMN1; SMN2ALDH1A1GPR139
SCHEMBL2407415 0.85 SMN1; SMN2 (0.77) HDAC8HDAC6SMN1; SMN2ALDH1A1GPR139
SCHEMBL2412518 0.83 GPR139 (0.65) SMN1; SMN2ALDH1A1GPR139TAS1R3TAS1R1
SCHEMBL2408198 0.82 MTOR (0.53) HDAC8HDAC6SMN1; SMN2ALDH1A1NPC1
SCHEMBL30929655 0.82 HDAC6 (1.00) HDAC8HDAC6SMN1; SMN2NPC1MEN1
SCHEMBL5242529 0.82 HDAC6 (1.00) HDAC8HDAC6SMN1; SMN2NPC1MEN1
SCHEMBL2405077 0.81 MMP9 (0.58) HDAC8HDAC6SMN1; SMN2ALDH1A1LMNA
SCHEMBL29793739 0.80 ALDH1A1 (0.62) SMN1; SMN2ALDH1A1GPR139LMNAATM
SCHEMBL23839968 0.80 MEN1 (0.59) SMN1; SMN2ALDH1A1GPR139ATMTAS1R3
SCHEMBL1320867 0.80 MEN1 (0.59) SMN1; SMN2ALDH1A1GPR139ATMTAS1R3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9382197-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-05 US disclosed
US-9382197-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-05 US disclosed
US-9382197-B2 Substituted hydroxamic acids and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-05 US disclosed
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-09-18 US disclosed
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-09-18 US disclosed
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2014-09-18 US disclosed
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed
WO-2011106632-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 WO disclosed
WO-2011106632-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 WO disclosed
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-09-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275093-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC10, HDAC1 HDAC8 15/4885HDAC6 1/4885SMN1; SMN2 975/4885
US-20110212969-A1 SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF HDAC6, HDAC10, HDAC1 HDAC8 15/4885HDAC6 1/4885SMN1; SMN2 975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.